EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions

Although EGFR-mut and ALK, RET and ROS1 fusion-positive NSCLC patients are treated first-line with tyrosine kinase inhibitors (TKIs), some present intrinsic resistance and could benefit from combined treatments.To determine the frequency of MET gene amplification, MET mutations and MET mRNA high expression baseline in a large cohort of EGFR-mut and ALK, ROS1 and RET fusion-positive NSCLC patients; (ii) To analyze paired biopsies of EGFR and fusion positive patients showing MET amplification at progression to targeted therapies.